In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010–2011 to 2014–2015 Japanese influenza seasons

Journal of Infection and Chemotherapy

Volumn 22, Issue 9, 2016, Pages 599-604

  Ikematsu, Hideyuki ^a   Kawai, Naoki ^a   Iwaki, Norio ^a   Kashiwagi, Seizaburo ^a  

^a Japan Physician's Association   (Japan)

Author keywords

A(H3N2); B; IC50; Influenza; Neuraminidase inhibitor; Resistance

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR; ENZYME INHIBITOR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IC50; IN VITRO STUDY; INFANT; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; MALE; MIDDLE AGED; NEWBORN; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; VIRUS ISOLATION; VIRUS RESISTANCE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; JAPAN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; JAPAN; MALE; MIDDLE AGED; NEURAMINIDASE; PRODUCT SURVEILLANCE, POSTMARKETING; YOUNG ADULT; ZANAMIVIR;

EID: 84992549189     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2016.06.002     Document Type: Article

References (16)

1. [1] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. J Infect Chemother 18 (2012), 529–533.
2. [2] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011–2012 season in Japan. J Infect Chemother 20 (2014), 77–80.
3. [3] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012–2013 season. J Infect Chemother 21 (2015), 39–42.
4. [4] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus circulating in the Japanese 2013–2014 season. J Infect Chemother 21 (2015), 634–638.
5. [5] Stockton, J., Ellis, J.S., Saville, M., Clewley, J.P., Zambon, M.C., Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 36 (1998), 2990–2995.
6. [6] Nakauchi, M., Takayama, I., Takahashi, H., Oba, K., Kubo, H., Kaida, A., et al. Real-time RT-PCR assays for discriminating influenza B virus Yamagata and Victoria lineages. J Virol Methods 205 (2014), 110–115.
7. [7] Yamashita, M., Tomozawa, T., Kakuta, M., Tokumitsu, A., Nasu, H., Kubo, S., CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53 (2008), 186–192.
8. [8] World Health Organization, Meeting of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 39 (2012), 369–380.
9. [9] Kawai, N., Ikematsu, H., Iwaki, N., Maeda, T., Satoh, I., Hirotsu, N., et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. Clin Infect Dis 43 (2006), 439–444.
10. [10] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season. J Infect Chemother 20 (2014), 81–85.
11. [11] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons. J Infect Chemother 20 (2014), 799–803.
12. [12] Ikematsu, H., Kawai, N., Iwaki, N., Kashiwagi, S., Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season. J Infect Chemother 21 (2015), 802–807.
13. [13] Fujisaki, S., Imai, M., Takashita, E., Taniwaki, T., Xu, H., Kishida, N., et al. Mutations at the monomer–monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. J Infect Chemother 19 (2013), 891–895.
14. [14] Burnham, A.J., Baranovich, T., Marathe, B.M., Armstrong, J., Webster, R.G., Govorkova, E.A., Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother 58 (2014), 2718–2730.
15. [15] Carrat, F., Flahault, A., Influenza vaccine: the challenge of antigenic drift. Vaccine 25 (2007), 6852–6862.
16. [16] http://www0.nih.go.jp/niid/idsc/iasr/Byogentai/Pdf/data2j.pdf.